Clinical Trial Update: Nab-paclitaxel Combined with Bevacizumab in the Treatment of Metastatic Extrapulmonary Neuroendocrine Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating nab-paclitaxel in combination with bevacizumab for metastatic extrapulmonary neuroendocrine carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extrapulmonary Neuroendocrine Carcinoma
• Neuroendocrine Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Peking University | Conditions: Neuroendocrine Carcinoma | Phase 2 | Status: COMPLETED